GEN Exclusives

More »

GEN News Highlights

More »
Jun 14, 2007

ProNAi Assigns Polymun as Manufacturer of DNAi-based Cancer Therapeutic

  • ProNAi Therapeutics signed a supply agreement with Polymun Scientific to manufacture the company's PNT2258 DNAi®-based cancer therapeutic.

    Polymun will use its cross-flow injector technology to produce ProNAi's liposome-formulated candidate, which is in the final stages of preclinical toxicology testing. ProNAi reports that it intends to bring PNT2258 to IND submission later this year.

    "ProNAi is confident that Polymun's manufacturing processes and technology are state-of-the-art and up to the task of formulating our oncology drug candidate, which features our novel oligo delivery method for the safe and effective administration of nucleic acid-based therapies," states Richard D. Gill, president and CEO of ProNAi.

     



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?